Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 0.44 |
| ▸ | MMP3 | P08254 | 10/20 | 0.44 |
| ▸ | MMP7 | P09237 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 6/20 | 0.41 |
| ▸ | MMP9 | P14780 | 7/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050036 | 1.00 | MMP1 (0.44) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL6417550 | 0.88 | MMP7 (0.53) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7050174 | 0.88 | MMP7 (0.53) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7051257 | 0.85 | MMP2 (0.49) | MMP1MMP3MMP2MMP9MMP13 | |
| SCHEMBL7046985 | 0.80 | MMP1 (0.45) | MMP1MMP3MMP7MMP8CA2 | |
| SCHEMBL7052597 | 0.79 | MME (0.54) | MMP7MMP2MMP9MMP13MMP8 | |
| SCHEMBL6418968 | 0.78 | CA2 (0.45) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7050945 | 0.78 | CA2 (0.45) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7050237 | 0.78 | MMP8 (0.49) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL7046360 | 0.78 | MMP8 (0.52) | MMP1MMP3MMP7MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0726903-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-07-16 | — | — | EP | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1047450-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0726903-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP1 20/4885MMP3 3/4885MMP7 9/4885 |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | MMP1 2/4885MMP3 3/4885MMP7 1/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP1 20/4885MMP3 3/4885MMP7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.